Charles River tops Q4 earnings and revenue estimates as margins expand, but shares dip, and organic growth declines across all segments.

Charles River Laboratories International, Inc. is a Hold as shares reflect both near-term headwinds & long-term disruption risks. Read more on CRL stock here.

The FDA issued a second CRL for rivoceranib and camrelizumab, with undisclosed reasons for non-approval. The combination therapy showed improved overall survival and progression-free survival compared ...

Charles River Laboratories International, Inc. CRL reported second-quarter 2025 adjusted earnings per share (EPS) of $3.12, which rose 11.4% year over year. The figure surpassed the Zacks Consensus ...